Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for Covert Hepatic Encephalopathy and SIBO in Liver Cirrhosis
NCT04244877Phase 3Withdrawn
- Sponsor
- MetroHealth Medical Center
- Start
- Sep 2021
- Primary completion
- May 2023
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of rifaximin in covert hepatic encephalopathy (CHE), small intestinal bacterial overgrowth (SIBO), sponsored by MetroHealth Medical Center. Planned start Sep 2021; status: withdrawn.
02
Drugs
rifaximin
03
Conditions
covert hepatic encephalopathy (CHE)small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT04244877.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04244877.